Accelerated Cholesteryl Ester Transfer

To discern the mechanism(s) that underlie abnormal cholesteryl ester transfer (CET) in patients with hypercholesterolemia, we have studied this dysfunctional step in reverse cholesterol transport in 13 subjects with genetically heterogeneous forms of hypercholesterolemia (HC). In all HC patients, the mass of CE transferred in whole plasma from HDL to VLDL and LDL increased rapidly initially and was significantly greater than in controls at 1, 2, and 4 h (P < 0.005). To further characterize this disturbance, we performed a series of recombination experiments. Combining HC d < 1.063 containing acceptor VLDL + LDL with the d > 1.063 fraction from controls containing donor HDL + CE-transfer protein (CETP) and not the converse combination showed the same characteristics of accelerated CET noted with intact HC plasma, indicating that abnormal transfer was associated with the HC acceptor lipoproteins. When HC VLDL and its subfractions and LDL were isolated separately and then combined with control d > 1.063 fractions, accelerated CET was only associated with VLDL1. Consistent with an acceleration of the neutral lipid transfer reaction occurring between HDL and VLDL1 in HC in vivo, we found that the triglyceride/CE ratio was decreased in HC VLDLI (P < 0.001), and increased in HDL (P < 0.25). CETP mass was significantly increased in HC plasma (HC 2.3±4 gg/ml vs. control 1.3±0.3 gg/ml; mean±SD; P < 0.025). This series ofobservations demonstrate thatCET is accelerated in the plasma ofHC patients, and this disturbance results from dysfunction of the VLDLI subfraction rather than an elevation ofCETP levels. Since an abnormality of this type in vivo can lead to the accumulation of potentially atherogenic CEenriched apoB-containing lipoproteins in plasma, it may be an additional previously unrecognized factor that increases cardiovascular risk in HC patients. (J. Clin. Invest. 1991. 87:12591265.)